A5089507490- Respiratory viral infections research
- Nosocomial Infections in ICU
- COVID-19 Clinical Research Studies
- Urinary Tract Infections Management
- Clostridium difficile and Clostridium perfringens research
- COVID-19 Impact on Reproduction
- Bacterial Identification and Susceptibility Testing
- Antimicrobial Resistance in Staphylococcus
- Antibiotic Use and Resistance
- Sepsis Diagnosis and Treatment
- Kawasaki Disease and Coronary Complications
- Central Venous Catheters and Hemodialysis
- Neonatal Respiratory Health Research
- Pneumonia and Respiratory Infections
- SARS-CoV-2 and COVID-19 Research
- Neonatal and Maternal Infections
- Surgical site infection prevention
- Antibiotics Pharmacokinetics and Efficacy
- Congenital Diaphragmatic Hernia Studies
- Streptococcal Infections and Treatments
- Virology and Viral Diseases
- Influenza Virus Research Studies
- Antibiotic Resistance in Bacteria
- Cardiac, Anesthesia and Surgical Outcomes
- Child Nutrition and Water Access
Pfizer (United States)
2023
Columbia University
2015-2022
New York Proton Center
2022
Communities In Schools of Orange County
2022
Manhattan Institute for Policy Research
2022
Oregon Medical Research Center
2022
Lindsay Unified School District
2022
University of Pittsburgh
2022
University of Calgary
2022
New York Hospital Queens
2016-2021
Clinical Characteristics of Children With SARS-CoV-2–Associated Pediatric Inflammatory Multisystem Syndrome
Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)–associated lower tract illness in newborns and infants is uncertain. Download a PDF Research Summary. In this phase 3, double-blind trial conducted 18 countries, we randomly assigned, 1:1 ratio, pregnant women at 24 through 36 weeks' gestation to receive single intramuscular injection 120 μg bivalent RSV prefusion F protein–based (RSVpreF) vaccine or placebo. The two primary efficacy end points...
<h3>Importance</h3> Descriptions of the coronavirus disease 2019 (COVID-19) experience in pediatrics will help inform clinical practices and infection prevention control for pediatric facilities. <h3>Objective</h3> To describe epidemiology, clinical, laboratory features patients with COVID-19 hospitalized at a children's hospital to compare these parameters between without severe disease. <h3>Design, Setting, Participants</h3> This retrospective review electronic medical records from...
Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develop severe or critical illness. Guidance therefore needed regarding use agents with potential activity against acute respiratory syndrome 2 pediatrics.
OBJECTIVE: To describe preterm birth frequency and newborn infant outcomes overall among children in the MATISSE (Maternal Immunization Study for Safety Efficacy) trial of maternal vaccination with bivalent respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVpreF) to protect infants against severe RSV-associated illness. METHODS: was a global, phase 3, randomized, double-blind trial. Pregnant individuals received single injections RSVpreF or placebo. Adverse events...
The disease caused by severe acute respiratory syndrome coronavirus 2, known as 2019, has resulted in a global pandemic. Reports are emerging of new hyperinflammatory related to 2019 children and adolescents. Centers for Disease Control Prevention designated this multisystem inflammatory children. Our objective was develop clinical inpatient protocol the evaluation, management, follow-up patients with syndrome.
Abstract Background Although coronavirus disease 2019 (COVID-19) is a mild infection in most children, small proportion develop severe or critical illness. Data describing agents with potential antiviral activity continue to expand such that updated guidance needed regarding use of these children. Methods A panel pediatric infectious diseases physicians and pharmacists from 20 geographically diverse North American institutions was convened. Through series teleconferences web-based surveys,...
In spring 2020, a novel hyperinflammatory process associated with severe acute respiratory syndrome coronavirus 2 multisystem inflammatory in children (MIS-C) was described. The long-term impact remains unknown. We report longitudinal outcomes from New York interdisciplinary follow-up program.All <21 years of age, admitted to NewYork-Presbyterian MIS-C were included. Children followed at 1 4 weeks, months, and 9 months postdischarge.In total, 45 MIS-C. median time last 5.8 (interquartile...
Background and Aims A newly recognized multisystem inflammatory syndrome in children (MIS‐C) has had a paradigm‐shifting effect on the perception of severe acute respiratory syndrome, coronavirus‐2 (SARS‐CoV‐2) illness severity children. We report clinical biochemical features liver involvement, comorbidities that present with hepatitis, substantial cohort patients. Approach Results This is retrospective study 44 patients MIS‐C admitted at Morgan Stanley Children’s Hospital New...
To assess whether multiplex polymerase chain reaction (mPCR) vs non-mPCR testing impacts the use of antibiotics, chest radiographs, and isolation precautions.We retrospectively compared precautions for patients <18 years old (excluding neonates) hospitalized at a tertiary referral center tested respiratory pathogens in emergency department or during first 2 hospital days, periods: June 2010-June 2012 (non-mPCR group) October 2012-May 2014 (mPCR group).Subjects (n = 2430) mPCR group were...
The epidemiology and clinical features of human coronaviruses (HCoVs) in children are not fully characterized.
In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for 2 novel virus-neutralizing monoclonal antibody therapies, bamlanivimab REGN-COV2 (casirivimab plus imdevimab), treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adolescents adults specified high-risk groups. This has challenged clinicians determine best approach use these products.A panel experts pediatric infectious diseases, diseases pharmacy, intensive care...
To examine whether patients with multisystem inflammatory syndrome in children (MIS-C) demonstrated well-defined clinical features distinct from other febrile outpatients, given the difficulties of seeing acute care visits during severe respiratory coronavirus 2 pandemic and risks associated both over- underdiagnosis MIS-C.
Background Widespread availability of rapid diagnostic testing for respiratory viruses allows more in‐depth studies human parainfluenza (HPIV). Objectives This study aimed to assess seasonality HPIV types 1‐4, clinical outcomes by type, and risk factors illness severity. Patients/Methods retrospective was performed from January 2013 December 2015 in children adults with HPIV, detected multiplex reverse transcription polymerase chain reaction, participating a community surveillance acute...
Abstract Background The epidemiology, clinical features, and resource utilization of respiratory syncytial virus (RSV) cases in the community hospital are not fully characterized. Methods We identified individuals all ages with laboratory‐confirmed RSV from two sources, a cohort undergoing surveillance for acute infections (ARIs) hospitalized patients same geographic area New York City between 2013 15. (antibiotic/steroid/ribavirin usage, chest X‐rays, respiratory‐support (continuous...
Starting in November 2020, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing monoclonal antibody therapies, including bamlanivimab monotherapy (now revoked), etesivimab, casirivimab imdevimab (REGEN-COV), sotrovimab, treatment or postexposure prophylaxis of Coronavirus disease 2019 (COVID-19) adolescents (≥12 years age) adults with certain high-risk conditions. Previous guidance is now updated based on new evidence...
14-21 days [7].While this was a small study of live virus shedding in COVID-19, numerous studies other viral infections have shown that is universally much shorter than PCR detection durations [8,9].The requirement to more 2 negative results order routinely remove isolation precautions for hospitalized patients requires additional data provide rigorous justification.Implications on testing resources and personal protective equipment use would be significant, there currently no evidence...